Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment

NCT04334460 is registered in ClinicalTrials.gov with Blade Therapeutics as lead sponsor.

NCT NCT04334460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04334460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment
Lead sponsor
Blade Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 4, 2020
Completion date
June 21, 2021
Enrollment
120 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov-2